[go: up one dir, main page]

NI200900079A - Novedosos anticuerpos antiproliferación. - Google Patents

Novedosos anticuerpos antiproliferación.

Info

Publication number
NI200900079A
NI200900079A NI200900079A NI200900079A NI200900079A NI 200900079 A NI200900079 A NI 200900079A NI 200900079 A NI200900079 A NI 200900079A NI 200900079 A NI200900079 A NI 200900079A NI 200900079 A NI200900079 A NI 200900079A
Authority
NI
Nicaragua
Prior art keywords
antibodies
new
present
antiproliferation antibodies
antiproliferation
Prior art date
Application number
NI200900079A
Other languages
English (en)
Inventor
Goetsch Liliane
Corvaia Nathalie
Bes Cédric
Haeuw Jean-François
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of NI200900079A publication Critical patent/NI200900079A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención está relacionada con anticuerpos aislados novedosos, o los compuestos derivados o fragmentos funcionales de los mismos, capaces de inhibir la proliferación de células tumorales in vitro y/o in vivo, dichos anticuerpos han sido obtenidos por tamizado funcional. Más particularmente, la presente invención se relaciona con el anticuerpo 6F4, específico para la proteína JAM-A, como así también con su uso para el tratamiento del cáncer. También están cubiertas las composiciones farmacéuticas compuestas por tales anticuerpos.
NI200900079A 2006-11-24 2009-05-06 Novedosos anticuerpos antiproliferación. NI200900079A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0610329A FR2909092B1 (fr) 2006-11-24 2006-11-24 Nouveaux anticorps anti-proliferation

Publications (1)

Publication Number Publication Date
NI200900079A true NI200900079A (es) 2010-11-10

Family

ID=37903981

Family Applications (1)

Application Number Title Priority Date Filing Date
NI200900079A NI200900079A (es) 2006-11-24 2009-05-06 Novedosos anticuerpos antiproliferación.

Country Status (27)

Country Link
US (2) US8071730B2 (es)
EP (1) EP2074148A1 (es)
JP (1) JP2010509931A (es)
KR (1) KR20090088878A (es)
CN (1) CN101535344B (es)
AU (1) AU2007324509B2 (es)
BR (1) BRPI0719323A2 (es)
CA (1) CA2670039A1 (es)
CL (1) CL2007003357A1 (es)
CR (1) CR10788A (es)
CU (1) CU23792A3 (es)
EC (1) ECSP099341A (es)
FR (1) FR2909092B1 (es)
GE (1) GEP20125629B (es)
GT (1) GT200900126A (es)
IL (1) IL198744A0 (es)
MA (1) MA30891B1 (es)
MX (1) MX2009005293A (es)
NI (1) NI200900079A (es)
NO (1) NO20092360L (es)
NZ (1) NZ576174A (es)
RU (1) RU2451689C2 (es)
SA (1) SA07280637B1 (es)
TN (1) TN2009000194A1 (es)
TW (1) TW200829602A (es)
UA (1) UA99602C2 (es)
WO (1) WO2008062063A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
WO2010002862A2 (en) * 2008-07-01 2010-01-07 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (fgfr3) binding proteins
CN102596249A (zh) * 2009-10-30 2012-07-18 默沙东公司 Ax1和ax189 pcsk9拮抗剂和变体
CN103298489A (zh) * 2010-10-29 2013-09-11 伊缪诺金公司 新型egfr结合分子及其免疫偶联物
EP2455403A1 (en) 2010-11-23 2012-05-23 Pierre Fabre Medicament Homogeneous humanized antibodies against JAM-A that inhibit proliferation
US20130287790A1 (en) * 2012-03-30 2013-10-31 The Board Of Trustees Of The Leland Standford Junior University Use of jam-a in diagnosing and treating leukemia
PT2888283T (pt) 2012-08-24 2018-11-16 Univ California Anticorpos e vacinas para serem utilizados no tratamento de cancros que expressam ror1 e inibição de metástases
KR20150097304A (ko) 2014-02-18 2015-08-26 삼성전자주식회사 항 EGFR DARPin을 포함하는 EGFR/HER2 이중 특이 항체
JP6966176B2 (ja) 2016-03-01 2021-11-10 イサム リサーチ ディベロップメント カンパニー オブ ザ ヘブルー ユニバーシティ オブ エルサレム エルティーディー． ヒトポリオウイルス受容体（ｐｖｒ）に特異的な抗体
MX2018016330A (es) 2016-06-27 2020-02-17 Univ California Combinaciones para tratamiento del cáncer.
RU2757394C2 (ru) * 2016-08-03 2021-10-14 Нексткьюр, Инк. Композиции и способы для модуляции передачи сигнала lair
CN109022366A (zh) * 2018-08-16 2018-12-18 江南大学 一株分泌抗左旋咪唑单克隆抗体的杂交瘤细胞株及其应用
CN114740108B (zh) * 2022-03-28 2023-07-14 天津键凯科技有限公司 一种聚合物修饰抗体类药物的修饰度的测定方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9604470D0 (sv) * 1996-12-04 1996-12-04 Tamas Bartfai Konsulting Ab Transmembrane component of tight junction
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US20030171568A1 (en) * 1998-09-16 2003-09-11 Avi Ashkenazi Use of A33 antigens and JAM-IT
TR200002885T2 (tr) * 1998-04-03 2000-12-21 Chugai Seiyaku Kabushiki Kaisha İnsan doku faktörüne (TF) karşı insanlaştırılmış antikor
NZ514091A (en) * 1999-03-11 2004-01-30 Rmf Dictagene S Vascular adhesion molecules and modulation of their function
WO2005060457A2 (en) * 2003-12-04 2005-07-07 Pdl Biopharma, Inc. Treatment of inflammatory bowel diseases with anti-ip-10 antibodies
WO2006008076A2 (en) * 2004-07-16 2006-01-26 Universita Degli Studi Di Milano Methods and agents stimulating the immune response
US7786266B2 (en) * 2005-05-12 2010-08-31 Oncotherapy Science, Inc. Methods for damaging cells using effector function of anti-DSC2 antibody
US7981628B2 (en) * 2006-04-28 2011-07-19 Oregon Health & Science University Monoclonal antibodies and their use

Also Published As

Publication number Publication date
AU2007324509A1 (en) 2008-05-29
CU23792A3 (es) 2012-03-15
NO20092360L (no) 2009-08-11
TN2009000194A1 (en) 2010-10-18
IL198744A0 (en) 2010-02-17
GEP20125629B (en) 2012-09-10
US8071730B2 (en) 2011-12-06
FR2909092A1 (fr) 2008-05-30
AU2007324509B2 (en) 2013-01-17
MX2009005293A (es) 2009-08-07
KR20090088878A (ko) 2009-08-20
SA07280637B1 (ar) 2012-04-11
GT200900126A (es) 2011-09-02
HK1132752A1 (en) 2010-03-05
BRPI0719323A2 (pt) 2014-02-04
CL2007003357A1 (es) 2008-04-04
CN101535344B (zh) 2013-10-16
WO2008062063A1 (en) 2008-05-29
JP2010509931A (ja) 2010-04-02
UA99602C2 (ru) 2012-09-10
US20120156191A1 (en) 2012-06-21
MA30891B1 (fr) 2009-11-02
NZ576174A (en) 2012-03-30
TW200829602A (en) 2008-07-16
RU2009123409A (ru) 2010-12-27
ECSP099341A (es) 2009-06-30
CN101535344A (zh) 2009-09-16
RU2451689C2 (ru) 2012-05-27
CA2670039A1 (en) 2008-05-29
CR10788A (es) 2009-06-23
EP2074148A1 (en) 2009-07-01
FR2909092B1 (fr) 2012-10-19
US20100092455A1 (en) 2010-04-15

Similar Documents

Publication Publication Date Title
NI200900079A (es) Novedosos anticuerpos antiproliferación.
CL2008000670A1 (es) Compuestos derivados de tiazolidindionas y oxazolidindionas sustituidas; composicion farmaceutica; proceso de preparacion de la composicion farmaceutica; y uso en el tratamiento de enfermedades tales como artritis reumatoide, epoc, cancer, entre otras.
CL2014000363A1 (es) Compuestos derivados de 1,2,5-oxadiazoles, inhibidores de indolamina 2,3-dioxigenasa; composicion farmaceutica; proceso para prepararlos; y su uso para el tratamiento de cancer, infeccion viral, depresion, desorden neurodegenerativo, trauma, cataratas, rechazo de transplante de un organo, enfermedades autoinmunes, entre otros.
NI201100082A (es) Compuestos de isoindolina para uso en el tratamiento de cáncer.
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
EA201500261A1 (ru) Конъюгаты антитело-лекарственное средство (adc), которые связываются с белками 158p1d7
CL2007002593A1 (es) Compuestos derivados de 4-heteroaril-piridina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como rechazo de organos transplantados, sindromes autoinmunes y cancer.
BR112012013664A2 (pt) rabdovírus oncolítico
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
MX2019013655A (es) Conjugados de anticuerpo farmaco (adc) que enlazan a proteinas 191p4d12.
CU24269B1 (es) 3- pirimidin- 4-il- oxazolidin- 2- onas inhibidores de la idh mutante
GT200500237A (es) Derivados de pirimidina
BRPI0923786C1 (pt) compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos e composições farmacêuticas compreendendo ditos compostos
BR112012025568A2 (pt) proteínas de ligação ao tnf-<244>.
EA201171435A1 (ru) Твердые фармацевтические композиции и способы их получения
BR112012023010A2 (pt) "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37"
MX2007014132A (es) Compuestos de diarilhidantoina.
BR112013033182A2 (pt) compostos imidazopiridinil-aminopiridina substituída
DOP2006000061A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
CO6571881A2 (es) Nuevos anticuerpos anti-cxcr4 humanizados para el tratamiento del cáncer
EA201390010A1 (ru) Замещенные триазолопиридины
BRPI0710331A2 (pt) Compostos heteroarila monocíclicos para tratamento de câncer e composição
EA201170659A1 (ru) Антитела к рецептору ii tgf-вета
CL2011000119A1 (es) Compuestos derivados de triazolo[4,3-a]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
UY32673A (es) Nuevas pirimidinas, composiciones farmaceuticas que las contienen, procedimientos de preparaciones y su aplicacion como medicamentos